<DOC>
	<DOCNO>NCT00316511</DOCNO>
	<brief_summary>This dose escalation study . Patients enrol cohort three patient , escalation dose next cohort determine base dose-limiting toxicity ( DLT ) previous cohort . This study aim identify maximum tolerate dose ( MTD ) intravenous L-NDDP . Once MTD determine , additional four patient enrol dose level . While MTD determine base safety data cohort 's first cycle L-NDDP therapy , patient may continue treatment additional cycle L-NDDP dose start dose document progression , unacceptable toxicity , another study criterion meet . Patients meet study criterion continue receive L-NDDP therapy time MTD determine may allow change L-NDDP dose MTD dose level . The study also determine pharmacokinetic profile L-NDDP administration . Clinical activity L-NDDP solid tumor patient assess tumor response use Response Evaluation Criteria Solid Tumors ( RECIST ) criterion . Clinical activity L-NDDP B-cell lymphoma patient assess use International Working Group recommendation .</brief_summary>
	<brief_title>Study L-NDDP ( Aroplatin ) Patients With Advanced Solid Malignancies B-Cell Lymphoma</brief_title>
	<detailed_description>This dose escalation study utilizes constant incremental dose increase 50 mg/m2 per cohort . Patients enrol cohort three patient , escalation dose next cohort determine base dose-limiting toxicity ( DLT ) previous cohort . DLT define adverse event ( AE ) severity grade 3 , 4 5 ( include serious life-threatening ) consider possibly , probably definitely relate L-NDDP ( CTCAE v3.0 ) , occur cycle 1 , exclude event occur completely resolve within 4-6 hour first dose L-NDDP ( infusion-related reaction ) . This study also aim identify maximum tolerate dose ( MTD ) intravenous L-NDDP , define dose level one six patient DLT . Once MTD determine , additional four patient enrol dose level ( total 10 patient MTD dose level ) . While MTD determine base safety data cohort 's first cycle L-NDDP therapy , patient may continue treatment additional cycle L-NDDP dose start dose document progression , unacceptable toxicity another study criterion meet . Patients meet study criterion continue receive L-NDDP therapy time MTD determine may allow change L-NDDP dose MTD dose level . The study also determine pharmacokinetic profile L-NDDP administration whole blood , plasma , urine sample draw , , L-NDDP administration . Clinical activity L-NDDP solid tumor patient assess tumor response use RECIST criterion . Clinical activity L-NDDP B-Cell lymphoma patient assess use International Working Group Recommendations .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>bis-neodecanoato-1,2-diaminocyclohexaneplatinum ( II )</mesh_term>
	<criteria>1 . Advanced solid malignancy Bcell lymphoma 2 . Less equal 5 anticancer treatment regimen , must conclude least four week prior first plan LNDDP administration 3 . Measurable disease 4 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 1 5 . New York Heart Association ( NYHA ) Class I II 6 . Greater equal 18 year age 7 . Absolute neutrophil count great equal 1.5 x 10^9/L 8 . Platelets great equal 100 x 10^9/L 9 . Creatinine le equal 1.5 x upper limit normal ( ULN ) 10 . ALT le 3 x ULN absence liver metastases ; le 5 x ULN presence liver metastasis . 11 . Hemoglobin great equal 10 g/dL 12 . Total bilirubin less equal 2 x ULN 13 . Female childbearing potential must negative serum pregnancy test 14 . Male female patient child produce potential must agree use contraception avoidance pregnancy measure study one month last LNDDP dose . 15 . Signed write informed consent must obtain document accord ICHGCP , local regulatory requirement , rule follow institution . 1 . Known active untreated brain metastasis 2 . Other ongoing systemic cancer therapy 3 . Hypersensitivity platinum compound 4 . Other active malignancy exception adequately treat insitu carcinoma uterine cervix , nonmelanoma skin cancer 5 . A marked baseline prolongation QT/QTc interval ( e.g . repeat demonstration [ least two assessment minimum 48 hour apart ] QTc interval &gt; 450 male &gt; 470 female ) history additional risk factor torsades de pointes use concomitant medication prolong QT/QTc interval 6 . Serious illness , opinion Principal Investigator , would prevent study completion 7 . Investigational therapy currently within four week prior plan first dose LNDDP 8 . Women pregnant breastfeeding exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>advanced solid malignancy</keyword>
	<keyword>B-cell lymphoma</keyword>
	<keyword>Aroplatin</keyword>
	<keyword>L-NDDP</keyword>
	<keyword>MTD</keyword>
	<keyword>advanced solid malignancy B-cell lymphoma</keyword>
</DOC>